ASRT vs. CUE, GNLX, ALLK, CTXR, IOBT, BYSI, ADAG, PMVP, ORMP, and RLMD
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Cue Biopharma (CUE), Genelux (GNLX), Allakos (ALLK), Citius Pharmaceuticals (CTXR), IO Biotech (IOBT), BeyondSpring (BYSI), Adagene (ADAG), PMV Pharmaceuticals (PMVP), Oramed Pharmaceuticals (ORMP), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Cue Biopharma (NASDAQ:CUE) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
In the previous week, Assertio had 6 more articles in the media than Cue Biopharma. MarketBeat recorded 13 mentions for Assertio and 7 mentions for Cue Biopharma. Assertio's average media sentiment score of 1.24 beat Cue Biopharma's score of 0.61 indicating that Cue Biopharma is being referred to more favorably in the media.
Cue Biopharma received 39 more outperform votes than Assertio when rated by MarketBeat users. However, 58.76% of users gave Assertio an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 10.2% of Cue Biopharma shares are owned by insiders. Comparatively, 3.2% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cue Biopharma has higher earnings, but lower revenue than Assertio. Cue Biopharma is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Cue Biopharma presently has a consensus price target of $8.00, suggesting a potential upside of 359.77%. Assertio has a consensus price target of $5.50, suggesting a potential upside of 439.22%. Given Cue Biopharma's higher probable upside, analysts clearly believe Assertio is more favorable than Cue Biopharma.
Assertio has a net margin of -234.40% compared to Assertio's net margin of -711.84%. Cue Biopharma's return on equity of 10.80% beat Assertio's return on equity.
Summary
Assertio beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
